Condition
Refractory B-Cell Non-Hodgkin Lymphoma clinical trials and research
As of November 12, 2026, Find a Trial lists 9 Refractory B-Cell Non-Hodgkin Lymphoma clinical trials that are recruiting, at sites in 2 countries (most in United States (8), China (1)). By phase: Phase 1 (5), Phase 1/2 (2), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 9Clinical trials
- 2Countries
Newest Refractory B-Cell Non-Hodgkin Lymphoma clinical trials
All recruiting trials (9)
-
Cognitive training to help brain function in people getting CAR-T therapy for relapsed or refractory blood cancers
A brain-training program given before and after CAR-T therapy is tested to see if it helps cognitive and neurological outcomes for adults with relapsed or refractory multiple myeloma or B-cell non-Hodgkin lymphoma.
-
Pomalidomide after CAR T-cell therapy for relapsed or refractory CD19+ B-cell leukemia or lymphoma
This phase 1 study tests whether pomalidomide, given after CD19 CAR T-cell therapy, is safe and may help people whose CD19+ B-cell leukemia or lymphoma has come back or not responded.
-
NK cell therapy with epcoritamab and tafasitamab for relapsed or treatment‑resistant B‑cell lymphoma
This trial will try whether adding donor-derived ONC-PluReceptor NK cells to the antibodies epcoritamab and tafasitamab helps control relapsed or refractory CD19/CD20-positive B‑cell non‑Hodgkin lymphoma.
-
Epcoritamab and Lenalidomide for Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
This phase 2 trial checks if the combination of epcoritamab and lenalidomide can help people with immune-related large B-cell lymphoma that hasn’t responded to treatment or has come back.
-
T-Cell Therapy for Adults with Relapsed B-Cell Non-Hodgkin's Lymphoma
This study is testing a new T-cell therapy to see if it can help adults with relapsed B-cell non-Hodgkin's lymphoma feel better.
-
Treatment of relapsed or refractory B-cell non-Hodgkin lymphoma with LUCAR-20SP
This study is testing a new CAR-T cell therapy called LUCAR-20SP to see if it can help adults with tough cases of relapsed or refractory B-cell non-Hodgkin lymphoma.
-
Treatment using genetically modified T-cells and a vaccine for B-Cell Non-Hodgkin Lymphoma
This study is testing a new treatment that uses specially modified immune cells and a vaccine to see if it can help people with tough-to-treat B-cell non-Hodgkin lymphoma feel better.
-
Combining Nivolumab and ASTX727 for B-Cell Lymphoma Treatment
This study is testing a new combination of two treatments, nivolumab and ASTX727, to see if it can help people with relapsed or hard-to-treat B-cell lymphoma feel better and live longer.
-
CD19 CAR-T cell therapy for treating relapsed B cell cancers
This study is testing a new treatment using modified immune cells to see if it can help people with relapsed B cell cancers feel better.
Related topics
Quick answers
How many Refractory B-Cell Non-Hodgkin Lymphoma clinical trials are recruiting right now?
9, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (8 trials), China (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 5, Phase 1/2: 2, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.